Saurabh Zanwar

Aug 28, 2024 | nature.com | Saurabh Zanwar |Jonas Paludo |Ronald S. Go |Joselle M. Cook |Sikander Ailawadhi |Thomas M Habermann | +10 more

An under-recognized source of bleeding in Waldenström macroglobulinemia (WM) is the development of an acquired von Willebrand syndrome (AVWS) [1]. In WM, the von Willebrand Factor (vWF) glycoprotein can be degraded due to autoantibody destruction, increased shear stress due to hyperviscosity, or sequestered due to adsorption onto malignant cells, leading to the development of AVWS (AVWS-WM) [1, 2].

Dec 9, 2023 | medium.com | Saurabh Zanwar

All employees should be salespeopleI was talking to one of the college seniors who happened to work in the same WeWork office. While discussing, he was asking me more about our tech stack and stuff. I was not at all aware of the reason. Upon discussing, he told me that he was thinking if we could be the customers of his company.

Aug 6, 2023 | onlinelibrary.wiley.com | Matthew Ho |Saurabh Zanwar |Jonas Paludo

2.2.3 Tisagenlecleucel/Kymriah™ Tisa-cel, a second-generation anti-CD19 CAR-T-cell product with a 4-1BB co-stimulatory domain, is currently FDA approved for relapsed or refractory DLBCL, ALL (for patients up to 25 years), and follicular lymphoma (after ≥2 lines of therapy) (Figure 1).

Jul 8, 2023 | onlinelibrary.wiley.com | Saurabh Zanwar |Matthew Ho |Yi Lin |Prashant Kapoor

Abstract Extramedullary multiple myeloma (EMM) can present either at initial diagnosis (de novo) or at disease relapse (secondary) and confers an aggressive clinical course. Limited data exist for choosing the optimal therapy for EMM and this remains an area of unmet clinical need. After excluding paraskeletal multiple myeloma and primary plasma cell leukemia, we identified 204 (68%) patients with secondary EMM and 95 (32%) with de novo EMM between January 01, 2000 and 31 December, 2021.